Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals

Journal of Virology

Volumn 86, Issue 8, 2012, Pages 4358-4369

  Dasgupta, Gargi ^a   Chentoufi, Aziz A ^a,b   Kalantari, Mina ^a,c   Falatoonzadeh, Payam ^a   Chun, Sookhee ^a   Lim, Chang Hyun ^a   Felgner, Philip L ^a   Davies, D Huw ^a   BenMohamed, Lbachir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN UL30; PROTEIN UL42; PROTEIN US10; PROTEIN US11; PROTEIN US4; PROTEOME; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN DETECTION; ARTICLE; ASYMPTOMATIC INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; GENE PROBE; GENETIC TRANSCRIPTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; MALE; MICROARRAY ANALYSIS; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CLUSTER ANALYSIS; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNODOMINANT EPITOPES; MALE; MIDDLE AGED; OPEN READING FRAMES; PROTEIN ARRAY ANALYSIS; PROTEOME; SEROEPIDEMIOLOGIC STUDIES; SEROLOGIC TESTS; YOUNG ADULT;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 84859405672     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07107-11     Document Type: Article

References (84)

1. Anderson KS, et al. 2008. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J. Proteome Res. 7:1490-1499.
2. Anderson KS, et al. 2011. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J. Proteome Res. 10: 85-96.
3. Barbour AG, et al. 2008. A genome-wide proteome array reveals a limitedset of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect. Immun. 76:3374-3389.
4. Belshe PB, et al. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366:34-43.
5. BenMohamed L, et al. 2003. Identification of novel immunodominant CD4+Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77:9463-9473.
6. BenMohamed L, et al. 1997. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1242-1253.
7. Bernstein DI, Spruance SL, Arora SS, Schroeder JL, Meng TC. 2005. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin. Infect. Dis. 41:808-814.
8. Bettahi I, Zhang X, Afifi RE, BenMohamed L. 2006. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by selfadjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol. 19:220-236.
9. Burbelo PD, Ching KH, Bush ER, Han BL, Iadarola MJ. 2010. Antibody-profiling technologies for studying humoral responses to infectious agents. Expert Rev. Vaccines 9:567-578.
10. Burbelo PD, et al. 2009. Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay. Clin. Vaccine Immunol. 16:366-371.
11. Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K. 1999. Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand nullmutant mice. J. Virol. 73:5196-5200.
12. Carmack MA, et al. 1996. T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and type 2. J. Infect. Dis. 174:899-906.
13. Chentoufi AA, et al. 2008. Asymptomatic human CD4+cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82:11792-11802.
14. Chentoufi AA, et al. 2010. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+T cell epitope-based vaccines against ocular herpes. J. Immunol. 184:2561-2571.
15. Chentoufi AA, et al. 2010. Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clin. Vaccine Immunol. 17:342-353.
16. Chentoufi AA, et al. 2008. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180:426-437.
17. Cunningham C, Davison AJ. 1993. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 197:116-124.
18. Dasgupta G, Nesburn AB, Wechsler SL, BenMohamed L. 2010. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol. 5:1-4.
19. Davies DH, et al. 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. U. S. A. 102:547-552.
20. Davies DH, et al. 2005. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79:11724-11733.
21. Davies DH, et al. 2008. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J. Virol. 82:652-663.
22. Durbin BP, Hardin JS, Hawkins DM, Rocke DM. 2002. A variancestabilizing transformation for gene-expression microarray data. Bioinformatics 18(Suppl 1):S105-S110.
23. Field PR, Ho DW, Irving WL, Isaacs D, Cunningham AL. 1993. The reliability of serological tests for the diagnosis of genital herpes: a critique. Pathology 25:175-179.
24. Fleming DT, et al. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-1111.
25. Freeman ML, Sheridan BS, Bonneau RH, Hendricks RL. 2007. Psychological stress compromises CD8_ T cell control of latent herpes simplex virus type 1 infections. J. Immunol. 179:322-328.
26. Gangappa S, Deshpande SP, Rouse BT. 1999. Bystander activation of CD4(+) T cells can represent an exclusive means of immunopathology in a virus infection. Eur. J. Immunol. 29:3674-3682.
27. Geiger KD, et al. 1997. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology 238:189-197.
28. Ghiasi H, Cai S, Slanina S, Nesburn AB, Wechsler SL. 1995. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res. 28: 147-157.
29. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. 1992. Baculovirusexpressed glycoprotein G of herpes simplex virus type 1 partially protects vaccinated mice against lethal HSV-1 challenge. Virology 190:233-239.
30. Ghiasi H, Perng GC, Cai S, Nesburn AB, Wechsler SL. 1996. The UL3 open reading frame of herpes simplex virus type 1 codes for a phosphoprotein. Virus Res. 44:137-142.
31. Ghiasi H, Slanina S, Nesburn AB, Wechsler SL. 1994. Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K. J. Virol. 68:2347-2354.
32. Herpetic Eye Disease Study Group. 1998. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N. Engl. J. Med. 339:300-306.
33. Hochberg Y, Benjamini Y. 1990. More powerful procedures for multiple significance testing. Stat. Med. 9:811-818.
34. Hosken N, et al. 2006. Diversity of the CD8+T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J. Virol. 80:5509-5515.
35. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. 2002. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18(Suppl 1): S96-S104.
36. Jing L, et al. 2008. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J. Virol. 82:7120-7134.
37. Jing L, et al. 2012. Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J. Clin. Invest. 122:654-673.
38. Kabilan L, et al. 1988. T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine. Proc. Natl. Acad. Sci. U. S. A. 85:5659-5663.
39. Kalantari-Dehaghi M, et al. 2012. Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling. J. Virol. 86:4328-4339.
40. Kalantari-Dehaghi M, et al. 2011. New targets of pemphigus vulgaris antibodies identified by protein array technology. Exp. Dermatol. 20:154-156.
41. Kim SK, et al. 2005. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J. Exp. Med. 201:523-533.
42. Kimberlin DW, et al. 2011. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N. Engl. J. Med. 365:1284-1292.
43. Klipper-Aurbach Y, et al. 1995. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med. Hypotheses 45:486-490.
44. Knaup B, Schunemann S, Wolff MH. 2000. Subclinical reactivation of herpes simplex virus type 1 in the oral cavity. Oral Microbiol. Immunol. 15:281-283.
45. Koelle DM. 2003. Expression cloning for the discovery of viral antigens and epitopes recognized by T cells. Methods 29:213-226.
46. Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L. 1994. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J. Infect. Dis. 169:956-961.
47. Koelle DM, et al. 2001. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J. Immunol. 166:4049-4058.
48. Koelle DM, Corey L. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113
49. Koelle DM, et al. 1994. Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J. Virol. 68:2803-2810.
50. Koelle DM, et al. 2003. Immunodominance among herpes simplex virusspecific CD8 T cells expressing a tissue-specific homing receptor. Proc. Natl. Acad. Sci. U. S. A. 100:12899-12904
51. Kriesel JD, et al. 2011. C21orf91 genotypes correlate with herpes simplex labialis (cold sore) frequency: description of a cold sore susceptibility gene. J. Infect. Dis. 204:1654-1662.
52. Leigh JF, Acharya N, Cevallos V, Margolis TP. 2008. Does asymptomaticshedding of herpes simplex virus on the ocular surface lead to falsepositive diagnostic PCR results? Br. J. Ophthalmol. 92:435-436.
53. Looker KJ, Garnett GP, Schmid GP. 2008. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 86:805-812.
54. Luevano M, et al. 2010. High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays. Virology 405:31-40.
55. Mikloska Z, Cunningham AL. 1998. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J. Gen. Virol. 79(Part2):353-361.
56. Mikloska Z, Kesson AM, Penfold ME, Cunningham AL. 1996. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma. J. Infect. Dis. 173:7-17.
57. Mott KR, et al. 2009. The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity. Invest. Ophthalmol. Vis. Sci. 50:2903-2912.
58. Mott KR, et al. 2007. Role of anti-glycoproteins D (anti-gD) and K (anti-gK) IgGs in pathology of herpes stromal keratitis in humans. Invest. Ophthalmol. Vis. Sci. 48:2185-2193.
59. Moutaftsi M, et al. 2007. Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+T cell responses. J. Immunol. 178:6814-6820.
60. Moutaftsi M, et al. 2010. Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol. 5:221-239.
61. Nesburn AB, et al. 2006. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4:178-187.
62. Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL. 1998. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 252:200-209.
63. Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL. 1998. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest. Ophthalmol. Vis. Sci. 39:1163-1170.
64. Nesburn AB, et al. 2005. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphateguanine adjuvant. Vaccine 23:873-883.
65. Nesburn AB, et al. 1998. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J. Virol. 72:7715-7721.
66. Nnedu ON, et al. 2011. Humoral immune responses to Plasmodium falciparum among HIV-1 infected Kenyan adults. Proteomics Clin. Appl. 5:613-623.
67. O'Farrell N. 1999. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes. Sex. Transm. Infect. 75:377-384.
68. O'Farrell N, Tovey SJ. 1994. High cumulative incidence of genital herpes amongst HIV-1 seropositive heterosexuals in south London. Int. J. STD AIDS 5:415-418.
69. Perng GC, et al. 1994. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J. Virol. 68:8045-8055.
70. Perng GC, et al. 1999. Herpes simplex virus type 1 serum neutralizing antibody titers increase during latency in rabbits latently infected with latency-associated transcript (LAT)-positive but not LAT-negative viruses. J. Virol. 73:9669-9672.
71. Posavad CM, et al. 2003. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity? J. Immunol. 170:4380-4388.
72. Schmid DS, et al. 1999. Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. J. Clin. Microbiol. 37:376-379.
73. Tengvall S, O'Hagan D, Harandi AM. 2008. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. Antiviral Res. 78:202-214.
74. Thomas J, Rouse BT. 1998. Immunopathology of herpetic stromal keratitis: discordance in CD4_ T cell function between euthymic host and reconstituted SCID recipients. J. Immunol. 160:3965-3970.
75. Tronstein E, et al. 2011. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 305:1441-1449.
76. Troye-Blomberg M, et al. 1988. T cell reactivity of defined peptides from a major Plasmodium falciparum vaccine candidate: the Pf155/RESA antigen. Immunol. Lett. 19:229-233.
77. Verjans GM, et al. 1998. Identification and characterization of herpes simplex virus-specific CD4+ T cells in corneas of herpetic stromal keratitis patients. J. Infect. Dis. 177:484-488.
78. Wald A, et al. 1997. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Invest. 99:1092-1097.
79. Wald A, et al. 2002. Genital shedding of herpes simplex virus among men. J. Infect. Dis. 186(Suppl 1):S34-S39.
80. Wald A, et al. 2000. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N. Engl. J. Med. 342:844-850.
81. Welsh RM, Selin LK. 2002. No one is naive: the significance of heterologous T-cell immunity. Nat. Rev. Immunol. 2:417-426.
82. Whitley RJ, Miller RL. 2001. Immunologic approach to herpes simplex virus. Viral Immunol. 14:111-118.
83. Whitley RJ, Roizman B. 2001. Herpes simplex virus infections. Lancet 357:1513-1518.
84. Xu F, et al. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973.